InflaRx (IFRX) Competitors $1.26 -0.21 (-14.29%) Closing price 04:00 PM EasternExtended Trading$1.27 +0.01 (+0.87%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IFRX vs. REPL, ZYBT, PRME, CGEM, KOD, CMPS, PRTA, ITOS, SLDB, and MBXShould you be buying InflaRx stock or one of its competitors? The main competitors of InflaRx include Replimune Group (REPL), Zhengye Biotechnology (ZYBT), Prime Medicine (PRME), Cullinan Therapeutics (CGEM), Kodiak Sciences (KOD), COMPASS Pathways (CMPS), Prothena (PRTA), iTeos Therapeutics (ITOS), Solid Biosciences (SLDB), and MBX Biosciences (MBX). These companies are all part of the "pharmaceutical products" industry. InflaRx vs. Its Competitors Replimune Group Zhengye Biotechnology Prime Medicine Cullinan Therapeutics Kodiak Sciences COMPASS Pathways Prothena iTeos Therapeutics Solid Biosciences MBX Biosciences Replimune Group (NASDAQ:REPL) and InflaRx (NASDAQ:IFRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, profitability, media sentiment, institutional ownership, risk, analyst recommendations, earnings and valuation. Do analysts recommend REPL or IFRX? Replimune Group presently has a consensus price target of $6.50, indicating a potential upside of 13.44%. InflaRx has a consensus price target of $6.20, indicating a potential upside of 392.06%. Given InflaRx's stronger consensus rating and higher possible upside, analysts plainly believe InflaRx is more favorable than Replimune Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Replimune Group 1 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.10InflaRx 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to REPL or IFRX? In the previous week, Replimune Group had 25 more articles in the media than InflaRx. MarketBeat recorded 34 mentions for Replimune Group and 9 mentions for InflaRx. InflaRx's average media sentiment score of 1.06 beat Replimune Group's score of 0.24 indicating that InflaRx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 4 Very Positive mention(s) 2 Positive mention(s) 25 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral InflaRx 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in REPL or IFRX? 92.5% of Replimune Group shares are held by institutional investors. Comparatively, 42.4% of InflaRx shares are held by institutional investors. 5.2% of Replimune Group shares are held by company insiders. Comparatively, 16.3% of InflaRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is REPL or IFRX more profitable? Replimune Group's return on equity of -69.34% beat InflaRx's return on equity.Company Net Margins Return on Equity Return on Assets Replimune GroupN/A -69.34% -52.81% InflaRx N/A -71.76%-57.68% Which has better earnings & valuation, REPL or IFRX? InflaRx has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than InflaRx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioReplimune GroupN/AN/A-$247.30M-$3.24-1.77InflaRx$180K469.91-$49.85M-$0.80-1.58 Which has more volatility & risk, REPL or IFRX? Replimune Group has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, InflaRx has a beta of 1.43, meaning that its share price is 43% more volatile than the S&P 500. SummaryInflaRx beats Replimune Group on 10 of the 14 factors compared between the two stocks. Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IFRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IFRX vs. The Competition Export to ExcelMetricInflaRxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$98.69M$3.20B$5.86B$10.15BDividend YieldN/A2.30%5.68%4.59%P/E Ratio-1.5721.1774.5225.93Price / Sales469.91463.28536.78122.58Price / CashN/A46.6837.5660.44Price / Book1.129.6112.166.29Net Income-$49.85M-$53.29M$3.28B$270.77M7 Day Performance-23.64%0.29%0.98%3.36%1 Month Performance51.26%8.91%7.20%6.41%1 Year Performance-11.27%13.14%63.06%28.26% InflaRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IFRXInflaRx3.2425 of 5 stars$1.26-14.3%$6.20+392.1%+2.1%$98.69M$180K-1.5760News CoveragePositive NewsShort Interest ↓Gap UpREPLReplimune Group3.9106 of 5 stars$5.81-1.4%$6.50+11.9%-42.0%$460.14MN/A-1.79210Trending NewsZYBTZhengye BiotechnologyN/A$7.87-19.3%N/AN/A$459.87M$25.53M0.00278News CoveragePRMEPrime Medicine3.2834 of 5 stars$3.40+1.8%$8.92+162.3%-0.2%$457.55M$4.96M-1.66234CGEMCullinan Therapeutics2.2423 of 5 stars$6.91-10.5%$26.80+287.8%-63.2%$456.05MN/A-2.1430News CoveragePositive NewsAnalyst ForecastHigh Trading VolumeKODKodiak Sciences3.8534 of 5 stars$8.55-0.2%$11.75+37.4%+301.6%$452.68MN/A-2.2590Positive NewsCMPSCOMPASS Pathways3.2148 of 5 stars$5.10+8.3%$16.29+219.3%-23.5%$451.88MN/A-2.77120Positive NewsHigh Trading VolumePRTAProthena3.2871 of 5 stars$8.21-2.1%$19.75+140.6%-59.7%$451.63M$135.16M-1.46130News CoverageITOSiTeos Therapeutics3.431 of 5 stars$10.15flat$15.50+52.7%N/A$448.73M$35M-2.1790Positive NewsSLDBSolid Biosciences2.9861 of 5 stars$5.56-3.3%$15.00+169.8%-29.1%$447.75M$8.09M-1.99100Positive NewsMBXMBX Biosciences2.8039 of 5 stars$12.92-10.3%$37.63+191.2%N/A$434.03MN/A-2.8536Positive News Related Companies and Tools Related Companies Replimune Group Competitors Zhengye Biotechnology Competitors Prime Medicine Competitors Cullinan Therapeutics Competitors Kodiak Sciences Competitors COMPASS Pathways Competitors Prothena Competitors iTeos Therapeutics Competitors Solid Biosciences Competitors MBX Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IFRX) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share InflaRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IFRX Stock Alerts